La cadena de opciones muestra datos clave de las opciones de acciones de ASR Nederland a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ASR Nederland..

ASR Nederland (OTC:ARNNY) Bolsa, Cadena de Opciones

ASR Nederland NV is an insurance company. The company offers a variety of insurance policies to its customers. The business segments are Non-life; Life; Banking, Asset Management; Distribution and Services and Holding and Other. The Non-life insurance entities offer Non-life insurance contracts. Its life insurance entities offer financial products such as life insurance contracts and life insurance contracts on behalf of policyholders. The Asset Management segment involves all activities related to asset management including investment property management. Its Distribution and Services segment includes activities related to the distribution of insurance contracts.

ASR NEDERLAND NV UNS/ADR by ASR Nederland N.V.

ASR Nederland NV

<a href="https://www.bloomberg.com/news/articles/2025-04-28/alibaba-rolls-out-latest-flagship-ai-model-in-post-deepseek-race">https://www.bloomberg.com/news/articles/2025-04-28/alibaba-rolls-out-latest-flagship-ai-model-in-post-deepseek-race</a>

News

General

BABA

'Alibaba Rolls Out Latest Flagship AI Model in Post-DeepSeek Race'- Bloomberg

Tevogen Bio Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares are ripping higher in Monday&#8217;s after-hours session after the company reaffirmed its <a href="https://www.benzinga.com/pressreleases/25/04/g45053606/tevogen-reaffirms-oncology-top-line-revenue-forecast-of-1-billion-in-launch-year-and-cumulative-5-">oncology pipeline revenue forecast</a>.
What Happened: After the market close on Monday, Tevogen Bio reaffirmed its oncology pipeline outlook, forecasting $1 billion in revenue in its launch year. The company also projected cumulative five-year estimated sales in the range of $10 billion and $14 billion. 
&#8220;With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,&#8221; said Ryan Saadi, founder and CEO of Tevogen Bio.
Tevogen Bio had a market cap of approximately $173.7 million as of Monday&#8217;s close. The company is set to hold its 2025 annual meeting of stockholders on June 23.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/45053893/amkor-technology-shares-climb-after-q1-revenue-beats-q2-revenue-guidance-above-estimates">Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates</a>
<h3 class="wp-block-heading">How To Buy TVGN Stock</h3>
By now you're likely curious about how to participate in the market for Tevogen Bio — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
TVGN Price Action: <a href="http://benzinga.com/quote/tvgn">Tevogen Bio shares</a> were up 39.76% after-hours, trading at $1.31 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data.
Photo: <a href="https://www.shutterstock.com/g/Timon+photography+world">T. Schneider</a>/Shutterstock.

Biotech

Guidance

After-Hours Center

Movers

TVGN

Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On?

UBS analyst Andrew Mok maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Buy and raises the price target from $117 to $130.

Price Target

Analyst Ratings

UBS Maintains Buy on Encompass Health, Raises Price Target to $130

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250428-1477852/1477852_bery4.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250428-1477852/1477852_bery4.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250428-1477852/1477852_bery4.pdf</a>

Markets

BERY

OKTA

Okta Will Replace Berry Global Group In The S&P MidCap 400 Effective Prior To The Opening Of Trading On Thursday, May 1

UBS analyst Brian Meredith maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Neutral and raises the price target from $303 to $304.

UBS Maintains Neutral on Chubb, Raises Price Target to $304

NXPL

NextPlat  Receives Nasdaq Letter Regarding Minimum Bid Requirements

UBS analyst Brian Meredith maintains The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Buy and raises the price target from $139 to $142.

UBS Maintains Buy on The Hartford Insurance Gr, Raises Price Target to $142

Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $29.10 million which beat the analyst consensus estimate of $28.21 million by 3.17 percent. This is a 33.36 percent increase over sales of $21.82 million the same period last year.

Earnings

Earnings Beats

EVLV

Evolv Technologies Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $29.10M Beat $28.21M Estimate

Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 50 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $27.36 million which beat the analyst consensus estimate of $26.32 million by 3.95 percent. This is a 35.51 percent increase over sales of $20.19 million the same period last year.

Evolv Technologies Q3 2024 Adj. EPS $(0.04) Beats $(0.06) Estimate, Sales $27.36M Beat $26.32M Estimate

Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBNK#NASDAQ">CBNK</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.72 by 22.22 percent. This is a 72.55 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $58.60 million which beat the analyst consensus estimate of $57.43 million by 2.03 percent. This is a 42.99 percent increase over sales of $40.98 million the same period last year.

CBNK

Capital Bancorp Q1 Adj. EPS $0.88 Beats $0.72 Estimate, Sales $58.60M Beat $57.43M Estimate

UBS analyst Myles Walton maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Neutral and raises the price target from $222 to $226.

UBS Maintains Neutral on L3Harris Technologies, Raises Price Target to $226

SunCar Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) reported $441.90 million in sales this quarter. This is a 21.49 percent increase over sales of $363.75 million the same period last year.

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Technology Group FY 2024 Revenue $441.90M Up From $363.75M YoY

UBS analyst Brian Meredith maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Buy and raises the price target from $73 to $78.

UBS Maintains Buy on WR Berkley, Raises Price Target to $78

UBS analyst Jay Sole maintains On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and raises the price target from $56 to $59.

ONON

UBS Maintains Buy on On Holding, Raises Price Target to $59

UBS analyst Gavin Parsons maintains Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) with a Sell and raises the price target from $62 to $63.

UBS Maintains Sell on Textron, Raises Price Target to $63

SJW Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NASDAQ">SJW</a>) affirms FY2025 Adj EPS guidance from $2.90-$3.00 to $2.90-$3.00 vs $2.97 analyst estimate..

SJW Gr Affirms FY2025 Adj EPS Guidance of $2.90-$3.00 vs $2.97 Est

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q2 Adj EPS of $0.41-$0.64 vs $0.52 analyst estimate. sees sales of $610.000 million-$680.000 million vs $643.53 million analyst estimate.

Teradyne Sees Q2 Adj EPS $0.41-$0.64 vs $0.52 Est; Sees Sales $610.000M-$680.000M vs $643.53M Est

SJW Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NYSE">SJW</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.36 by 38.89 percent. This is a 38.89 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $167.60 million which beat the analyst consensus estimate of $159.03 million by 5.39 percent. This is a 12.19 percent increase over sales of $149.38 million the same period last year.

SJW Gr Q1 Adj. EPS $0.50 Beats $0.36 Estimate, Sales $167.60M Beat $159.03M Estimate

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.62 by 20.97 percent. This is a 47.06 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $685.68 million which beat the analyst consensus estimate of $680.51 million by 0.76 percent. This is a 14.31 percent increase over sales of $599.82 million the same period last year.

Teradyne Q1 Adj. EPS $0.75 Beats $0.62 Estimate, Sales $685.68M Beat $680.51M Estimate

Transocean, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) released its first-quarter results after Monday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/04/g45052677/transocean-ltd-reports-first-quarter-2025-results"> from the report. </a>
The Details: Transocean reported first-quarter losses of 10 cents per share, which missed the analyst consensus estimate for losses of nine cents. Quarterly revenue clocked in at $906 million, beating the consensus estimate of $885.7 million.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, Transocean reported: 
<ul>
<li>Contract drilling revenues for the quarter decreased sequentially by $46 million to $906 million. </li>
<li>Operating and maintenance expense was $618 million, compared with $579 million in the prior quarter. The sequential increase was the result of an unfavorable legal outcome in the first quarter, a favorable legal settlement in the fourth quarter and increased costs related to a rig in shipyard, partially offset by lower in-service maintenance costs across the fleet.</li>
<li>General and administrative expense was $50 million, down from $56 million in the fourth quarter, due primarily to decreased legal and professional fees.</li>
</ul>
&#8220;The Transocean team delivered a solid quarter, with an adjusted EBITDA of $244 million on revenues of $906 million,&#8221; said CEO Jeremy Thigpen. &#8220;We also improved our balance sheet with the repayment of $210 million in outstanding debt.&#8221;
&#8220;While uncertain macroeconomic conditions have resulted in near-term market volatility, including commodity prices, Transocean is very well-positioned to navigate this evolving landscape.&nbsp;In addition to continuing to deliver strong operating performance across our highly contracted fleet, we remain engaged in constructive conversations with our customers on opportunities several years in the future,&#8221; Thigpen added. 
RIG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Transocean stock was up 1.30% after-hours at $2.31 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Comments

ASR Nederland

ASR Nederland (ARNNY) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL